Page last updated: 2024-11-05

5-nitro-2-toluidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-Nitro-2-toluidine, also known as 2-amino-5-nitrotoluene, is a nitroaniline derivative. It's a solid, yellow to orange compound. Its synthesis is typically achieved through the nitration of o-toluidine. 5-Nitro-2-toluidine is a versatile intermediate used in the production of various dyes, pigments, and pharmaceuticals. It's also a precursor for the synthesis of other important organic compounds. Research on 5-nitro-2-toluidine focuses on its synthesis, reactivity, and potential applications in diverse industries.'

5-nitro-2-toluidine: structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-nitro-o-toluidine : A C-nitro compound in which the nitro compound is meta to the amino group and para to the methyl group of o-toluidine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7444
CHEMBL ID324642
CHEBI ID66891
SCHEMBL ID2313
MeSH IDM0178958

Synonyms (141)

Synonym
MLS002152874
5-nitro-ortho-toluidine
1-amino-2-methyl-5-nitrobenzene
fast scarlet mn4t base
c.i. azoic diazo component no. 12
hsdb 4144
rcra waste no. u181
ci azoic diazo component 12
ai3-01557
rcra waste number u181
brn 0879021
azoic diazo component 12
einecs 202-765-8
ci 37105
5-nitro-2-methylaniline
ccris 483
nsc 8947
5-nitro-2-toluidine
2-methyl-5-nitro-benzeneamine
MLS000517118
smr000343278
2-methyl-5-nitroaniline
fast scarlet gc base
amarthol fast scarlet g base
devol scarlet g salt
5-nitro-o-toluidine
nci-c01843
nsc8947
scarlet g base
pnot
o-toluidine, 5-nitro-
azogene fast scarlet g
fast scarlet g
2-methyl-5-nitrobenzenamine
3-nitro-6-methylaniline
kayaku scarlet g base
symulon scarlet g base
amarthol fast scarlet g salt
fast scarlet base g
diazo fast scarlet g
azoene fast scarlet gc base
naphthanil scarlet g base
benzenamine, 2-methyl-5-nitro-
azoic diazo component 12, base
6-methyl-3-nitroaniline
fast red sg base
sugai fast scarlet g base
2-amino-4-nitrotoluene
fast scarlet m4nt base
fast scarlet g salt
hiltonil fast scarlet gc base
naphtoelan fast scarlet g base
nsc-8947
devol scarlet b
mitsui scarlet g base
fast scarlet t base
fast scarlet base j
c.i. 37105
azoene fast scarlet gc salt
dainichi fast scarlet g base
4-nitro-2-aminotoluene
naphtoelan fast scarlet g salt
scarlet base ciba ii
lithosol orange r base
daito scarlet base g
fast scarlet g base
diabase scarlet g
c.i. azoic diazo component 12
scarlet base irga ii
wln: zr b1 enw
hiltonil fast scarlet g salt
99-55-8
fast scarlet j salt
hiltonil fast scarlet g base
azofix scarlet g salt
lake scarlet g base
scarlet base nsp
2-methyl-5-nitro-aniline
NCGC00091592-01
inchi=1/c7h8n2o2/c1-5-2-3-6(9(10)11)4-7(5)8/h2-4h,8h2,1h
2-methyl-5-nitroaniline, 98%
5-nitro-o-toluidine, analytical standard
2-methyl-5-nitroaniline, 95%
NCGC00091592-02
AH-034/32850060
CHEMBL324642
chebi:66891 ,
N0115
AKOS000119136
NCGC00091592-03
NCGC00091592-04
2-methyl-5-nitro aniline
HMS2679N16
dtxcid60959
NCGC00254217-01
tox21_300134
cas-99-55-8
NCGC00259494-01
tox21_201945
dtxsid4020959 ,
STL163886
unii-433myh2dwm
433myh2dwm ,
ec 202-765-8
4-12-00-01807 (beilstein handbook reference)
2-methyl-5-nitrophenylamine
AM20060769
o-amino-p-nitrotoluene
5-nitro-o-toluidine [hsdb]
5-nitro-ortho-toluidine [iarc]
FT-0620719
FT-0620718
2-methyl-5-nitroaniline-
2-amino-4-nitro toluene
4-nitro-2-amino-1-methylbenzene
2-methyl,5-nitroaniline
2-methyl-5-nitro-phenylamine
2-amino-4-nitro-toluene
SCHEMBL2313
(2-methyl-5-nitrophenyl)amine
fast scarlet m 4nt base
1-methyl-2-amino-4-nitrobenzene
azoene fast scarlet g salt
conazoic diazo ab
Q-100917
CS-M3392
F2190-0478
2-methyl-5-nitroaniline, 98+%
mfcd00007741
2-methyl-5-nitroaniline, analytical standard
2-amino-4-nitrotoluene 10 microg/ml in acetonitrile
BCP24941
Q27135494
SB10516
STR03005
D77508
amino-nitro-toluene
3-nitro-6-methylanilin
2-amino-4-nitrotoluene 100 microg/ml in acetonitrile
EN300-17407
Z56926522
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency36.99040.000221.22318,912.5098AID1259243; AID1259247
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.06310.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency53.14090.001022.650876.6163AID1224838; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.01780.000214.376460.0339AID588532
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency14.68310.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency25.48550.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency5.17260.001530.607315,848.9004AID1224841; AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency11.03090.000229.305416,493.5996AID743069; AID743075
aryl hydrocarbon receptorHomo sapiens (human)Potency55.42850.000723.06741,258.9301AID743085; AID743122
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency50.97080.000627.21521,122.0200AID651741; AID743202
gemininHomo sapiens (human)Potency3.66260.004611.374133.4983AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency26.85450.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID433903Hepatotoxicity in mouse assessed as carcinogenic potency2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals.
AID233323Activity expressed by taste potency (taste intensity relative to sucrose on a mole/mole basis)1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Structure--taste relationship of perillartine and nitro- and cyanoaniline derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's1 (11.11)18.2507
2000's3 (33.33)29.6817
2010's3 (33.33)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.74 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]